subject area of
- A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186 Journal Articles
- A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia Journal Articles
- A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer Journal Articles
- A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer Journal Articles
- A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium Journal Articles
- A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study Journal Articles
- BAY 43-9006: Early Clinical Data in Patients with Advanced Solid Malignancies Journal Articles
- Changes in Liver Volume Observed Following Sorafenib and Liver Radiation Therapy Journal Articles
- Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology. Journal Articles
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma Journal Articles
- Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial Journal Articles
- Metastatic renal cell cancer treatments: An indirect comparison meta-analysis Journal Articles
- Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review Journal Articles
- Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors Journal Articles
- Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors Journal Articles
- Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma Conferences
- Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Journal Articles
- Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Journal Articles
- Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program Journal Articles
- Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Journal Articles
- Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors Journal Articles
- Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab Journal Articles
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN) Journal Articles
- Sorafenib and Radiation Therapy for the Treatment of Advanced Hepatocellular Carcinoma Journal Articles
- Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium Journal Articles
- Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial. Journal Articles
- Targeted therapy for metastatic renal cell carcinoma Journal Articles
- The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review Journal Articles
- Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma Journal Articles
- Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and meta-analysis Journal Articles
- USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation Journal Articles